title: Anti-inflammatory effects of a novel peptide designed to bind with NF-kappaB p50 subunit.
abstract: OBJECTIVE
  To explore the anti-inflammatory effects of a novel peptide designed to bind with the NF-kappaB p50 subunit.
  
  
  METHODS
  The affinity of the peptide binding with p50 was measured with a biosensor. Levels of tumor necrosis factor-alpha(TNF-alpha) and interleukin 6 (IL-6) from a human acute monocytic leukemia cell line (THP-1) treated with lipopolysaccharide (LPS) were measured using the ELISA method. In vivo anti-inflammatory effects of the peptide were tested with phorbol myristate acetate (PMA)-induced ear edema and zymosan A-induced peritonitis in mice.
  
  
  RESULTS
  The peptide has the ability to interact with the NF-kappaB p50 subunit and can effectively inhibit TNF-alpha and IL-6 production in the THP-1 cell line, PMA-induced ear edema and zymosan A-induced peritonitis in mice.
  
  
  CONCLUSIONS
  The peptide may have therapeutic potential for the treatment of local acute inflammation.
authors.affiliation: Bioengineering College, Chongqing University, Chongqing 400044, China.
authors.forename: Zhen-ping
authors.initials: ZP
authors.lastname: Wang
authors.forename: Shao-xi
authors.initials: SX
authors.lastname: Cai
authors.forename: Dong-bo
authors.initials: DB
authors.lastname: Liu
authors.forename: Xiang
authors.initials: X
authors.lastname: Xu
authors.forename: Hua-ping
authors.initials: HP
authors.lastname: Liang
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001665:Binding Sites; D015374:Biosensing Techniques; D045744:Cell Line, Tumor; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D007948:Leukemia, Monocytic, Acute / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D052002:NF-kappa B p50 Subunit / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism* / Q000494:pharmacology; D010538:Peritonitis / Q000139:chemically induced / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015054:Zymosan
chemical_list: D000893:Anti-Inflammatory Agents; D015850:Interleukin-6; D052002:NF-kappa B p50 Subunit; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate